UFT plus carboplatin for head and neck cancer

Masato Fujii, Yoshihiro Ohno, Yutaka Tokumaru, Yorihisa Imanishi, Minoru Kanke, Toshiki Tomita, Taku Yamashita

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Cisplatin plus fluorouracil (5-FU) is widely accepted as neoadjuvant and adjuvant chemotherapy in the treatment of head and neck squamous cell carcinoma; UFT is also an active agent against this disease. In the first retrospective study, we examined the efficacy of UFT as adjuvant chemotherapy in patients with maxillary cancer. The 5-year survival rate of those treated with UFT vs those not treated was 71.4% vs 23.8%, respectively. In the second study we developed the carboplatin plus UFT regimen - as a modification of cisplatin plus 5-FU -and studied its efficacy and toxicity in patients with advanced head and neck squamous cell carcinoma. These patients received UFT plus carboplatin. The objective response rate was 53.1%; grade ≥ 3 leukopenia, anemia, and thrombocytopenia were rare. These findings suggest that UFT plus carboplatin in the outpatient setting is feasible for patients with head and neck squamous cell carcinoma.

Original languageEnglish
Pages (from-to)72-75
Number of pages4
JournalOncology
Volume14
Issue number10 SUPPL. 9
Publication statusPublished - 2000

Fingerprint

Carboplatin
Head and Neck Neoplasms
Fluorouracil
Adjuvant Chemotherapy
Cisplatin
Leukopenia
Thrombocytopenia
Anemia
Outpatients
Survival Rate
Retrospective Studies
Carcinoma, squamous cell of head and neck
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Fujii, M., Ohno, Y., Tokumaru, Y., Imanishi, Y., Kanke, M., Tomita, T., & Yamashita, T. (2000). UFT plus carboplatin for head and neck cancer. Oncology, 14(10 SUPPL. 9), 72-75.

UFT plus carboplatin for head and neck cancer. / Fujii, Masato; Ohno, Yoshihiro; Tokumaru, Yutaka; Imanishi, Yorihisa; Kanke, Minoru; Tomita, Toshiki; Yamashita, Taku.

In: Oncology, Vol. 14, No. 10 SUPPL. 9, 2000, p. 72-75.

Research output: Contribution to journalArticle

Fujii, M, Ohno, Y, Tokumaru, Y, Imanishi, Y, Kanke, M, Tomita, T & Yamashita, T 2000, 'UFT plus carboplatin for head and neck cancer', Oncology, vol. 14, no. 10 SUPPL. 9, pp. 72-75.
Fujii M, Ohno Y, Tokumaru Y, Imanishi Y, Kanke M, Tomita T et al. UFT plus carboplatin for head and neck cancer. Oncology. 2000;14(10 SUPPL. 9):72-75.
Fujii, Masato ; Ohno, Yoshihiro ; Tokumaru, Yutaka ; Imanishi, Yorihisa ; Kanke, Minoru ; Tomita, Toshiki ; Yamashita, Taku. / UFT plus carboplatin for head and neck cancer. In: Oncology. 2000 ; Vol. 14, No. 10 SUPPL. 9. pp. 72-75.
@article{9760984e63fa45118fe4e44c6b2fa571,
title = "UFT plus carboplatin for head and neck cancer",
abstract = "Cisplatin plus fluorouracil (5-FU) is widely accepted as neoadjuvant and adjuvant chemotherapy in the treatment of head and neck squamous cell carcinoma; UFT is also an active agent against this disease. In the first retrospective study, we examined the efficacy of UFT as adjuvant chemotherapy in patients with maxillary cancer. The 5-year survival rate of those treated with UFT vs those not treated was 71.4{\%} vs 23.8{\%}, respectively. In the second study we developed the carboplatin plus UFT regimen - as a modification of cisplatin plus 5-FU -and studied its efficacy and toxicity in patients with advanced head and neck squamous cell carcinoma. These patients received UFT plus carboplatin. The objective response rate was 53.1{\%}; grade ≥ 3 leukopenia, anemia, and thrombocytopenia were rare. These findings suggest that UFT plus carboplatin in the outpatient setting is feasible for patients with head and neck squamous cell carcinoma.",
author = "Masato Fujii and Yoshihiro Ohno and Yutaka Tokumaru and Yorihisa Imanishi and Minoru Kanke and Toshiki Tomita and Taku Yamashita",
year = "2000",
language = "English",
volume = "14",
pages = "72--75",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "10 SUPPL. 9",

}

TY - JOUR

T1 - UFT plus carboplatin for head and neck cancer

AU - Fujii, Masato

AU - Ohno, Yoshihiro

AU - Tokumaru, Yutaka

AU - Imanishi, Yorihisa

AU - Kanke, Minoru

AU - Tomita, Toshiki

AU - Yamashita, Taku

PY - 2000

Y1 - 2000

N2 - Cisplatin plus fluorouracil (5-FU) is widely accepted as neoadjuvant and adjuvant chemotherapy in the treatment of head and neck squamous cell carcinoma; UFT is also an active agent against this disease. In the first retrospective study, we examined the efficacy of UFT as adjuvant chemotherapy in patients with maxillary cancer. The 5-year survival rate of those treated with UFT vs those not treated was 71.4% vs 23.8%, respectively. In the second study we developed the carboplatin plus UFT regimen - as a modification of cisplatin plus 5-FU -and studied its efficacy and toxicity in patients with advanced head and neck squamous cell carcinoma. These patients received UFT plus carboplatin. The objective response rate was 53.1%; grade ≥ 3 leukopenia, anemia, and thrombocytopenia were rare. These findings suggest that UFT plus carboplatin in the outpatient setting is feasible for patients with head and neck squamous cell carcinoma.

AB - Cisplatin plus fluorouracil (5-FU) is widely accepted as neoadjuvant and adjuvant chemotherapy in the treatment of head and neck squamous cell carcinoma; UFT is also an active agent against this disease. In the first retrospective study, we examined the efficacy of UFT as adjuvant chemotherapy in patients with maxillary cancer. The 5-year survival rate of those treated with UFT vs those not treated was 71.4% vs 23.8%, respectively. In the second study we developed the carboplatin plus UFT regimen - as a modification of cisplatin plus 5-FU -and studied its efficacy and toxicity in patients with advanced head and neck squamous cell carcinoma. These patients received UFT plus carboplatin. The objective response rate was 53.1%; grade ≥ 3 leukopenia, anemia, and thrombocytopenia were rare. These findings suggest that UFT plus carboplatin in the outpatient setting is feasible for patients with head and neck squamous cell carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0034305266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034305266&partnerID=8YFLogxK

M3 - Article

C2 - 11098499

AN - SCOPUS:0034305266

VL - 14

SP - 72

EP - 75

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 10 SUPPL. 9

ER -